Paradigm Biocapital Advisors’s Edgewise Therapeutics EWTX Stock Holding History

Paradigm Biocapital Advisors’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$232M	Buy	7,365,038 +823,828	+13%	+$23.8M	4.74%	5
2025 Q4	$162M	Buy	6,541,210 +371,079	+6%	+$7.45M	4.14%	11
2025 Q3	$100M	Buy	6,170,131 +27,787	+0.5%	+$394K	2.85%	12
2025 Q2	$80.5M	Buy	6,142,344 +1,747,788	+40%	+$25.2M	3.44%	8
2025 Q1	$96.7M	Sell	4,394,556 -99,373	-2%	-$2.61M	4.43%	7
2024 Q4	$120M	Buy	4,493,929 +1,704,757	+61%	+$54.3M	4.17%	7
2024 Q3	$74.4M	Buy	2,789,172 +463,723	+20%	+$9.22M	2.52%	10
2024 Q2	$41.9M	Sell	2,325,449 -120,924	-5%	-$2.11M	1.6%	20
2024 Q1	$44.6M	Buy	+2,446,373	New	+$38.9M	1.57%	21

Other funds holding EWTX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM